Performance Watch Report Released On Softbank Mobile's ?1.45 Trillion Business Securitization

  • ID: 1771281
  • Standard & Poors
1 of 3

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

TOKYO (Standard & Poor's) Dec. 10, 2007--Standard & Poor's Ratings Services today published a Japanese-language report titled "Performance Watch: WBS Funding Company; J-WBS Funding K.K." This report is organized in accordance with Standard & Poor's surveillance process for this transaction. In the report, Standard & Poor's details industry trends and Softbank Mobile's business performance, including the net increase in subscribers it has enjoyed since the closing date of the securitization deal. The trends and numbers are compared with original forecasts formulated by Standard & Poor's in its rating analysis, and their potential impact on the current ratings on the transaction is analyzed. It is integral for the business securitization market in Japan that market participants gain a deeper understanding of...

Companies mentioned in this report are: WBS Funding Co.,J-WBS Funding KK
Action: General Comment

Note: Product cover images may vary from those shown
2 of 3

WBS Funding Co.,J-WBS Funding KK

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.